JP2018197259A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018197259A5 JP2018197259A5 JP2018153543A JP2018153543A JP2018197259A5 JP 2018197259 A5 JP2018197259 A5 JP 2018197259A5 JP 2018153543 A JP2018153543 A JP 2018153543A JP 2018153543 A JP2018153543 A JP 2018153543A JP 2018197259 A5 JP2018197259 A5 JP 2018197259A5
- Authority
- JP
- Japan
- Prior art keywords
- prostaglandin
- hydrocortisone
- cell
- glucocorticoid
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 20
- -1 Desoxycorton Chemical compound 0.000 claims 16
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims 16
- 150000003180 prostaglandins Chemical class 0.000 claims 16
- 239000000556 agonist Substances 0.000 claims 10
- 210000004027 cell Anatomy 0.000 claims 10
- 239000003862 glucocorticoid Substances 0.000 claims 10
- 230000037361 pathway Effects 0.000 claims 10
- 229960000890 hydrocortisone Drugs 0.000 claims 8
- 229960003957 dexamethasone Drugs 0.000 claims 6
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 6
- 229960005205 prednisolone Drugs 0.000 claims 6
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 4
- 229960002842 clobetasol Drugs 0.000 claims 4
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 claims 4
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 claims 4
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 claims 4
- XWTIDFOGTCVGQB-FHIVUSPVSA-N fluocortin butyl Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)C(=O)OCCCC)[C@@]2(C)C[C@@H]1O XWTIDFOGTCVGQB-FHIVUSPVSA-N 0.000 claims 4
- 229960001067 hydrocortisone acetate Drugs 0.000 claims 4
- 239000000018 receptor agonist Substances 0.000 claims 4
- 229940044601 receptor agonist Drugs 0.000 claims 4
- 229960005294 triamcinolone Drugs 0.000 claims 4
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims 4
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 claims 3
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 claims 3
- 230000005012 migration Effects 0.000 claims 3
- 238000013508 migration Methods 0.000 claims 3
- VHRSUDSXCMQTMA-UHFFFAOYSA-N 11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-3-one Chemical compound CC12C=CC(=O)C=C1C(C)CC1C2C(O)CC2(C)C(O)(C(=O)CO)CCC21 VHRSUDSXCMQTMA-UHFFFAOYSA-N 0.000 claims 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims 2
- QAOBBBBDJSWHMU-WMBBNPMCSA-N 16,16-dimethylprostaglandin E2 Chemical compound CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O QAOBBBBDJSWHMU-WMBBNPMCSA-N 0.000 claims 2
- MYYIMZRZXIQBGI-HVIRSNARSA-N 6alpha-Fluoroprednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3C[C@H](F)C2=C1 MYYIMZRZXIQBGI-HVIRSNARSA-N 0.000 claims 2
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 claims 2
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims 2
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims 2
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 claims 2
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 claims 2
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims 2
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims 2
- WYQPLTPSGFELIB-JTQPXKBDSA-N Difluprednate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2CC[C@@](C(=O)COC(C)=O)(OC(=O)CCC)[C@@]2(C)C[C@@H]1O WYQPLTPSGFELIB-JTQPXKBDSA-N 0.000 claims 2
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 claims 2
- POPFMWWJOGLOIF-XWCQMRHXSA-N Flurandrenolide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O POPFMWWJOGLOIF-XWCQMRHXSA-N 0.000 claims 2
- DERCOWNWEPPIHD-UHFFFAOYSA-N [17-(2-chloroacetyl)-9-fluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] butanoate Chemical compound C1CC2=CC(=O)C=CC2(C)C2(F)C1C1CC(C)C(C(=O)CCl)(OC(=O)CCC)C1(C)CC2O DERCOWNWEPPIHD-UHFFFAOYSA-N 0.000 claims 2
- 229940022663 acetate Drugs 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 229950000210 beclometasone dipropionate Drugs 0.000 claims 2
- 229940092705 beclomethasone Drugs 0.000 claims 2
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims 2
- 229960002537 betamethasone Drugs 0.000 claims 2
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims 2
- 229960000870 betamethasone benzoate Drugs 0.000 claims 2
- SOQJPQZCPBDOMF-YCUXZELOSA-N betamethasone benzoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(F)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@@H]1C)C(=O)CO)C(=O)C1=CC=CC=C1 SOQJPQZCPBDOMF-YCUXZELOSA-N 0.000 claims 2
- 229960004311 betamethasone valerate Drugs 0.000 claims 2
- SNHRLVCMMWUAJD-SUYDQAKGSA-N betamethasone valerate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O SNHRLVCMMWUAJD-SUYDQAKGSA-N 0.000 claims 2
- CQFNOACVVKSEOJ-VBQPQCOESA-N bronilide Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O CQFNOACVVKSEOJ-VBQPQCOESA-N 0.000 claims 2
- 229960004436 budesonide Drugs 0.000 claims 2
- 229960003728 ciclesonide Drugs 0.000 claims 2
- BMCQMVFGOVHVNG-TUFAYURCSA-N cortisol 17-butyrate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CO)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O BMCQMVFGOVHVNG-TUFAYURCSA-N 0.000 claims 2
- 229960004544 cortisone Drugs 0.000 claims 2
- 229960003662 desonide Drugs 0.000 claims 2
- WBGKWQHBNHJJPZ-LECWWXJVSA-N desonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O WBGKWQHBNHJJPZ-LECWWXJVSA-N 0.000 claims 2
- 229960002593 desoximetasone Drugs 0.000 claims 2
- VWVSBHGCDBMOOT-IIEHVVJPSA-N desoximetasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@@H]2O VWVSBHGCDBMOOT-IIEHVVJPSA-N 0.000 claims 2
- 229960004875 difluprednate Drugs 0.000 claims 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical group CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- AAXVEMMRQDVLJB-BULBTXNYSA-N fludrocortisone Chemical compound O=C1CC[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 AAXVEMMRQDVLJB-BULBTXNYSA-N 0.000 claims 2
- 229960004511 fludroxycortide Drugs 0.000 claims 2
- 229960003469 flumetasone Drugs 0.000 claims 2
- WXURHACBFYSXBI-GQKYHHCASA-N flumethasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O WXURHACBFYSXBI-GQKYHHCASA-N 0.000 claims 2
- 229940042902 flumethasone pivalate Drugs 0.000 claims 2
- JWRMHDSINXPDHB-OJAGFMMFSA-N flumethasone pivalate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)COC(=O)C(C)(C)C)(O)[C@@]2(C)C[C@@H]1O JWRMHDSINXPDHB-OJAGFMMFSA-N 0.000 claims 2
- 229960000676 flunisolide Drugs 0.000 claims 2
- 229960000442 flunisolide hemihydrate Drugs 0.000 claims 2
- 229940043075 fluocinolone Drugs 0.000 claims 2
- 229960001347 fluocinolone acetonide Drugs 0.000 claims 2
- 229960000785 fluocinonide Drugs 0.000 claims 2
- 229960005355 fluocortin Drugs 0.000 claims 2
- 229950008509 fluocortin butyl Drugs 0.000 claims 2
- 229960001048 fluorometholone Drugs 0.000 claims 2
- FAOZLTXFLGPHNG-KNAQIMQKSA-N fluorometholone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FAOZLTXFLGPHNG-KNAQIMQKSA-N 0.000 claims 2
- 229960000618 fluprednisolone Drugs 0.000 claims 2
- 229960002714 fluticasone Drugs 0.000 claims 2
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims 2
- 229960000289 fluticasone propionate Drugs 0.000 claims 2
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims 2
- 229960000671 formocortal Drugs 0.000 claims 2
- QNXUUBBKHBYRFW-QWAPGEGQSA-N formocortal Chemical compound C1C(C=O)=C2C=C(OCCCl)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O QNXUUBBKHBYRFW-QWAPGEGQSA-N 0.000 claims 2
- 229960002475 halometasone Drugs 0.000 claims 2
- GGXMRPUKBWXVHE-MIHLVHIWSA-N halometasone Chemical compound C1([C@@H](F)C2)=CC(=O)C(Cl)=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O GGXMRPUKBWXVHE-MIHLVHIWSA-N 0.000 claims 2
- 229960002453 hydrocortisone aceponate Drugs 0.000 claims 2
- MFBMYAOAMQLLPK-FZNHGJLXSA-N hydrocortisone aceponate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(C)=O)(OC(=O)CC)[C@@]1(C)C[C@@H]2O MFBMYAOAMQLLPK-FZNHGJLXSA-N 0.000 claims 2
- 229960001524 hydrocortisone butyrate Drugs 0.000 claims 2
- 229960001798 loteprednol Drugs 0.000 claims 2
- YPZVAYHNBBHPTO-MXRBDKCISA-N loteprednol Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)OCCl)[C@@H]4[C@@H]3CCC2=C1 YPZVAYHNBBHPTO-MXRBDKCISA-N 0.000 claims 2
- 229960001810 meprednisone Drugs 0.000 claims 2
- PIDANAQULIKBQS-RNUIGHNZSA-N meprednisone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)CC2=O PIDANAQULIKBQS-RNUIGHNZSA-N 0.000 claims 2
- 229960004584 methylprednisolone Drugs 0.000 claims 2
- 229960001293 methylprednisolone acetate Drugs 0.000 claims 2
- 238000010232 migration assay Methods 0.000 claims 2
- 230000001617 migratory effect Effects 0.000 claims 2
- 229960001664 mometasone Drugs 0.000 claims 2
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 claims 2
- 229960002744 mometasone furoate Drugs 0.000 claims 2
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 claims 2
- 229960004123 mometasone furoate monohydrate Drugs 0.000 claims 2
- 229960004618 prednisone Drugs 0.000 claims 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 2
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 claims 2
- 229960001487 rimexolone Drugs 0.000 claims 2
- QTTRZHGPGKRAFB-OOKHYKNYSA-N rimexolone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CC)(C)[C@@]1(C)C[C@@H]2O QTTRZHGPGKRAFB-OOKHYKNYSA-N 0.000 claims 2
- 229960002117 triamcinolone acetonide Drugs 0.000 claims 2
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 claims 2
- 229940070710 valerate Drugs 0.000 claims 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims 2
- 101150066398 CXCR4 gene Proteins 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000005779 cell damage Effects 0.000 claims 1
- 208000037887 cell injury Diseases 0.000 claims 1
- 230000014509 gene expression Effects 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000000451 tissue damage Effects 0.000 claims 1
- 231100000827 tissue damage Toxicity 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161566494P | 2011-12-02 | 2011-12-02 | |
| US61/566,494 | 2011-12-02 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017041708A Division JP6415616B2 (ja) | 2011-12-02 | 2017-03-06 | 虚血を処置する改善された方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020112693A Division JP2020158540A (ja) | 2011-12-02 | 2020-06-30 | 虚血を処置する改善された方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018197259A JP2018197259A (ja) | 2018-12-13 |
| JP2018197259A5 true JP2018197259A5 (enExample) | 2019-02-07 |
| JP6727261B2 JP6727261B2 (ja) | 2020-07-22 |
Family
ID=48536234
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014544867A Active JP6106688B2 (ja) | 2011-12-02 | 2012-11-29 | 虚血を処置する改善された方法 |
| JP2017041708A Active JP6415616B2 (ja) | 2011-12-02 | 2017-03-06 | 虚血を処置する改善された方法 |
| JP2018153543A Active JP6727261B2 (ja) | 2011-12-02 | 2018-08-17 | 虚血を処置する改善された方法 |
| JP2020112693A Withdrawn JP2020158540A (ja) | 2011-12-02 | 2020-06-30 | 虚血を処置する改善された方法 |
| JP2022070033A Pending JP2022093428A (ja) | 2011-12-02 | 2022-04-21 | 虚血を処置する改善された方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014544867A Active JP6106688B2 (ja) | 2011-12-02 | 2012-11-29 | 虚血を処置する改善された方法 |
| JP2017041708A Active JP6415616B2 (ja) | 2011-12-02 | 2017-03-06 | 虚血を処置する改善された方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020112693A Withdrawn JP2020158540A (ja) | 2011-12-02 | 2020-06-30 | 虚血を処置する改善された方法 |
| JP2022070033A Pending JP2022093428A (ja) | 2011-12-02 | 2022-04-21 | 虚血を処置する改善された方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US10111907B2 (enExample) |
| EP (2) | EP2785350B1 (enExample) |
| JP (5) | JP6106688B2 (enExample) |
| ES (1) | ES2682255T3 (enExample) |
| WO (1) | WO2013082241A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2785350B1 (en) * | 2011-12-02 | 2018-05-02 | Fate Therapeutics, Inc. | Improved methods of treating ischemia |
| CN104066837B (zh) | 2011-12-02 | 2020-12-08 | 菲特治疗公司 | 增强的干细胞组合物 |
| WO2014093531A1 (en) * | 2012-12-11 | 2014-06-19 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Modulation of myofiber repair by anti-myostatin in strategies with stem cells |
| US10851412B2 (en) | 2013-03-15 | 2020-12-01 | Fate Therapeutics, Inc. | Cell potency assay for therapeutic potential |
| US9943545B2 (en) | 2013-03-15 | 2018-04-17 | Fate Therapeutics, Inc. | Stem cell culture media and methods of enhancing cell survival |
| KR101674253B1 (ko) * | 2014-07-16 | 2016-11-08 | 연세대학교 산학협력단 | 트랜스웰 및 케모카인을 이용한 줄기세포의 분리 방법 |
| HK1247958A1 (zh) * | 2015-05-05 | 2018-10-05 | 菲特治疗公司 | T淋巴细胞的调节 |
| BR112018001232A2 (pt) | 2015-07-21 | 2018-09-25 | The Children's Medical Center Corporation | pd-l1 que expressa células-tronco hematopoéticas e usos |
| WO2017026838A1 (ko) * | 2015-08-12 | 2017-02-16 | 주식회사 차바이오텍 | 향상된 탯줄 유래 부착형 줄기세포, 그의 제조방법 및 용도 |
| JP6648259B2 (ja) * | 2015-08-12 | 2020-02-14 | チャ バイオテック カンパニー リミテッド | 向上された臍帯由来付着型幹細胞、その製造方法及びその用途 |
| WO2017046369A1 (en) * | 2015-09-16 | 2017-03-23 | Centre National De La Recherche Scientifique (Cnrs) | Gelling compositions for treating malignant tumours and/or preventing tumour recurrence |
| EP4538365A3 (en) * | 2016-03-04 | 2025-07-30 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for muscle regeneration using prostaglandin e2 |
| KR102002671B1 (ko) * | 2016-11-11 | 2019-07-23 | 사회복지법인 삼성생명공익재단 | 2ｄｇ를 이용한 줄기세포 역량 향상 방법 |
| GB2578539B (en) | 2017-06-09 | 2022-08-10 | Univ Leland Stanford Junior | Compositions and methods for preventing or treating muscle conditions |
| WO2019060708A1 (en) | 2017-09-22 | 2019-03-28 | The Children's Medical Center Corporation | TREATMENT OF TYPE 1 DIABETES AND AUTOIMMUNE DISEASES OR DISORDERS |
| WO2019102761A1 (ja) | 2017-11-24 | 2019-05-31 | Ｋｙｂ株式会社 | 筒型リニアモータ |
| GB202211232D0 (en) | 2022-08-02 | 2022-09-14 | Heptares Therapeutics Ltd | Prostaglandin EP4 receptor agonist compounds |
| CN116966302B (zh) * | 2023-06-28 | 2025-11-25 | 华中科技大学同济医学院附属协和医院 | Areg的新用途 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5420033A (en) | 1989-06-21 | 1995-05-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Epithelial cell line expressing a cystic fibrosis phenotype |
| US5077049A (en) | 1989-07-24 | 1991-12-31 | Vipont Pharmaceutical, Inc. | Biodegradable system for regenerating the periodontium |
| EP0676470A1 (en) | 1989-10-16 | 1995-10-11 | Amgen Inc. | Stem cell factor |
| US5061620A (en) | 1990-03-30 | 1991-10-29 | Systemix, Inc. | Human hematopoietic stem cell |
| US5635387A (en) | 1990-04-23 | 1997-06-03 | Cellpro, Inc. | Methods and device for culturing human hematopoietic cells and their precursors |
| AU2882992A (en) | 1991-11-06 | 1993-06-07 | Arthur A. Axelrad | Cell culture medium |
| US5460964A (en) | 1992-04-03 | 1995-10-24 | Regents Of The University Of Minnesota | Method for culturing hematopoietic cells |
| US5442033A (en) | 1993-07-20 | 1995-08-15 | Ethicon, Inc. | Liquid copolymers of epsilon-caprolactone and lactide |
| AU702871B2 (en) | 1993-08-23 | 1999-03-11 | Nexell Therapeutics Inc. | (In vitro) growth of neutrophil and megakaryocyte precursors in serum-free media |
| US5409813A (en) | 1993-09-30 | 1995-04-25 | Systemix, Inc. | Method for mammalian cell separation from a mixture of cell populations |
| US5648331A (en) | 1994-08-26 | 1997-07-15 | G.D. Searle & Co. | Method of inhibiting tissue ischemia and reperfusion injury |
| US5677136A (en) | 1994-11-14 | 1997-10-14 | Systemix, Inc. | Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof |
| US5753516A (en) | 1995-02-03 | 1998-05-19 | Heagy; Wyrta E. | Screening method for ligands of the EBI-1 receptor |
| AU6125396A (en) | 1995-06-07 | 1996-12-30 | Novartis Ag | Serum-free media for primitive hematopoietic cells and metho ds of use thereof |
| US5854033A (en) | 1995-11-21 | 1998-12-29 | Yale University | Rolling circle replication reporter systems |
| US5945337A (en) | 1996-10-18 | 1999-08-31 | Quality Biological, Inc. | Method for culturing CD34+ cells in a serum-free medium |
| US6372796B1 (en) | 1996-11-13 | 2002-04-16 | Cold Spring Harbor Laboratory | Therapeutic uses for nitric oxide inhibitors |
| US6191109B1 (en) | 1997-10-31 | 2001-02-20 | Children's Hospital, Inc. | Methods of treating intestinal ischemia using heparin-binding epidermal growth factor |
| AU2183900A (en) | 1998-12-24 | 2000-07-31 | Alcon Laboratories, Inc. | Ep4 receptor agonists for treatment of dry eye |
| GB9904281D0 (en) | 1999-02-24 | 1999-04-21 | Reneuron Ltd | Transplantation |
| HK1048302A1 (zh) | 1999-08-13 | 2003-03-28 | 大正制药株式会社 | 前列腺素衍生物 |
| BR0015781A (pt) | 1999-11-24 | 2002-12-31 | Ono Pharmaceutical Co | Composição farmacêutica para tratamento de doenças associadas à diminuição de massa óssea |
| TWI247606B (en) | 1999-11-24 | 2006-01-21 | Ono Pharmaceutical Co | Treating agent for osteopenic diseases |
| ATE327751T1 (de) | 2000-01-31 | 2006-06-15 | Pfizer Prod Inc | Verwendung von aktivatoren des prostaglandinrezeptores 4 zur behandlung von akuter oder chronischer niereninsuffizienz |
| US20020013294A1 (en) | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
| FR2825261B1 (fr) | 2001-06-01 | 2003-09-12 | Maco Pharma Sa | Ligne de prelevement du sang placentaire comprenant une poche de rincage |
| US7179643B2 (en) | 2001-06-14 | 2007-02-20 | Reliance Life Sciences Pvt. Ltd. | Device and a process for expansion of haemopoeitic stem cells for therapeutic use |
| AU2002350352A1 (en) | 2001-12-21 | 2003-07-15 | Mount Sinai Hospital | Cellular compositions and methods of making and using them |
| HUE029417T2 (en) | 2002-10-10 | 2017-02-28 | Ono Pharmaceutical Co | Microspheres containing ONO-1301 |
| AU2004216898A1 (en) | 2003-03-04 | 2004-09-16 | Pfizer Products Inc. | Use of EP2 selective receptor agonists in medical treatment |
| EP1601759A4 (en) | 2003-03-07 | 2007-02-14 | Gamida Cell Ltd | EXPANSION OF RENEWABLE STEM CELL POPULATIONS USING PI-3 KINASE MODULATORS |
| WO2004081196A2 (en) | 2003-03-11 | 2004-09-23 | Qlt Usa Inc. | Formulations for cell- schedule dependent anticancer agents |
| US6747037B1 (en) | 2003-06-06 | 2004-06-08 | Allergan, Inc. | Piperidinyl prostaglandin E analogs |
| US8309608B2 (en) | 2003-11-06 | 2012-11-13 | Sanofi-Aventis Deutschland Gmbh | Use of eNOS transcription enhancers in the cell therapy of ischemic heart diseases |
| EP1701729B1 (en) | 2003-12-31 | 2018-05-02 | Warsaw Orthopedic, Inc. | Improved bone matrix compositions and methods |
| JP4086816B2 (ja) | 2004-07-01 | 2008-05-14 | 株式会社Ｎｅｃ情報システムズ | Ｂｇａ部品搭載基板の層数見積もり装置及び方法並びに層数見積もりプログラム |
| US7147626B2 (en) | 2004-09-23 | 2006-12-12 | Celgene Corporation | Cord blood and placenta collection kit |
| CN101103101B (zh) | 2004-09-24 | 2012-10-10 | 成血管细胞系统公司 | 增强间充质前体细胞（mpc）的增生和/或存活的方法 |
| WO2006047476A2 (en) | 2004-10-26 | 2006-05-04 | Allergan, Inc. | Therapeutic and delivery methods of prostaglandin ep4 agonists |
| WO2006078886A2 (en) | 2005-01-18 | 2006-07-27 | Irm Llc | Compounds and compositions as wnt signaling pathway modulators |
| EP1859028B1 (en) | 2005-02-10 | 2015-12-02 | Regents Of The University Of Minnesota | Vascular endothelial cells |
| WO2007056423A1 (en) | 2005-11-07 | 2007-05-18 | The General Hospital Corporation | Methods and compositions for modulation of stem cell aging |
| DE102005062741A1 (de) | 2005-12-22 | 2007-06-28 | Bayer Schering Pharma Ag | Fluorene und Carbazole als Liganden des EP2 Rezeptors |
| GB2447191B (en) | 2005-12-22 | 2011-08-03 | Es Cell Int Pte Ltd | Direct differentiation of cardiomyocytes from human embryonic stem cells |
| EP1999255A2 (en) | 2006-03-24 | 2008-12-10 | The Children's Medical Center Corporation | Method to modulate hematopoietic stem cell growth |
| WO2008021475A2 (en) | 2006-08-16 | 2008-02-21 | The General Hospital Corporation | Compositions and methods for hematopoietic stem cell expansion or for modulating angiogenesis |
| KR20080042761A (ko) | 2006-11-10 | 2008-05-15 | 문찬일 | 렙틴을 이용한 줄기세포 증식방법 |
| EP2094839B1 (en) | 2006-12-08 | 2020-02-05 | University of Rochester | Expansion of hematopoietic stem cells |
| US8871752B2 (en) | 2008-02-19 | 2014-10-28 | Sucampo Ag | Method for modulating stem cell growth |
| US20110165128A1 (en) | 2008-03-07 | 2011-07-07 | Columbia University In The City Of New York | Homing in mesenchymal stem cells |
| US8092822B2 (en) | 2008-09-29 | 2012-01-10 | Abbott Cardiovascular Systems Inc. | Coatings including dexamethasone derivatives and analogs and olimus drugs |
| EP3031907B1 (en) * | 2008-11-06 | 2021-01-06 | Indiana University Research and Technology Corporation | Materials and methods to enhance hematopoietic stem cells engraftment procedures |
| BRPI0920976A2 (pt) | 2008-12-03 | 2015-08-18 | Amorcyte Inc | Composições que melhoram a perfusão da area de infarto e metodos de restauração da lesão vascular. |
| EP3533445A1 (en) | 2009-03-19 | 2019-09-04 | Fate Therapeutics, Inc. | Compositions comprising cyclic amp enhancers and/or ep ligands, and methods of preparing and using the same |
| US11459545B2 (en) * | 2009-11-15 | 2022-10-04 | Indiana University Research And Technology Corporation | Methods to enhance delivery and engraftment of stem cells including the identification of specific prostaglandin E2 receptors |
| CN103167876B (zh) | 2010-08-12 | 2016-08-31 | 菲特治疗公司 | 改进的造血干细胞和祖细胞疗法 |
| EP2785350B1 (en) * | 2011-12-02 | 2018-05-02 | Fate Therapeutics, Inc. | Improved methods of treating ischemia |
| CN104066837B (zh) | 2011-12-02 | 2020-12-08 | 菲特治疗公司 | 增强的干细胞组合物 |
-
2012
- 2012-11-29 EP EP12852924.5A patent/EP2785350B1/en active Active
- 2012-11-29 US US14/362,385 patent/US10111907B2/en active Active
- 2012-11-29 JP JP2014544867A patent/JP6106688B2/ja active Active
- 2012-11-29 EP EP18169424.1A patent/EP3381456A1/en not_active Withdrawn
- 2012-11-29 ES ES12852924.5T patent/ES2682255T3/es active Active
- 2012-11-29 WO PCT/US2012/066984 patent/WO2013082241A2/en not_active Ceased
-
2017
- 2017-03-06 JP JP2017041708A patent/JP6415616B2/ja active Active
-
2018
- 2018-08-17 JP JP2018153543A patent/JP6727261B2/ja active Active
- 2018-09-19 US US16/135,889 patent/US10980838B2/en active Active
-
2020
- 2020-06-30 JP JP2020112693A patent/JP2020158540A/ja not_active Withdrawn
-
2021
- 2021-04-12 US US17/228,128 patent/US20220054553A1/en not_active Abandoned
-
2022
- 2022-04-21 JP JP2022070033A patent/JP2022093428A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019047820A5 (enExample) | ||
| HRP20200495T1 (hr) | Sastavi za liječenje gastrointestinalne upale | |
| JP2010540671A5 (enExample) | ||
| Jacob et al. | Corticosteroid classes: a quick reference guide including patch test substances and cross-reactivity | |
| JP2012532889A5 (enExample) | ||
| JP2015505829A5 (enExample) | ||
| Johnson | Development of fluticasone propionate and comparison with other inhaled corticosteroids | |
| HRP20161279T1 (hr) | Kombinirani preparati s antagonistom citokina i ortikosteroidom | |
| RU2015133465A (ru) | Стабилизированные композиции, содержащие гиалуроновую кислоту | |
| US20090264392A1 (en) | Treating eosinophilic esophagitis | |
| JP2008500987A5 (enExample) | ||
| JP2010530435A5 (enExample) | ||
| JP2008297310A5 (enExample) | ||
| JP2023530166A5 (enExample) | ||
| JP2004512297A5 (enExample) | ||
| SI2393477T1 (en) | Use of a glucocorticoid composition for the treatment of severe and uncontrolled asthma | |
| WO2006026083A2 (en) | Nasal delivery of cyclodextrin complexes of anti-inflammatory steroids | |
| JP2015506983A5 (enExample) | ||
| JP2006518382A5 (enExample) | ||
| KR20080080387A (ko) | 스테로이드의 경시적 안정성이 개선된 외용 제제 | |
| RU2014113906A (ru) | Терапевтическое применение эктоина | |
| JP2014526448A5 (enExample) | ||
| JP2018529767A (ja) | 自己免疫疾患及び自己炎症疾患の治療方法 | |
| Koldzic-Zivanovic et al. | Regulation of adrenal glucocorticoid synthesis by interleukin-10: a preponderance of IL-10 receptor in the adrenal zona fasciculata | |
| RU2005129276A (ru) | Применение стероидов для лечения субъектов, страдающих заболеванием глаз |